Advertisement

Tumor Biology

, Volume 36, Issue 8, pp 5925–5929 | Cite as

Genetic variability of glutathione S-transferases influences treatment outcome of breast cancer

  • Liang Zhou
  • Anzhong Huang
  • Dawei Zhang
  • Junliang Yao
  • Yong Zhang
  • Xuejiao Li
Research Article

Abstract

We investigated the relationship between the clinical outcome and the GSTM1 null/present, GSTT1 null/present, and GSTP1 IIe105Val polymorphisms in breast cancer patients with chemotherapy. A total of 420 consecutive breast cancer patients diagnosed between January 2010 and December 2011 were eligible for inclusion in our retrospective study. The designs of the assay and SNP genotyping of GSTM1 null/present, GSTT1 null/present, and GSTP1 IIe105Val were performed using the Sequenom MassARRAY platform. In the univariate analysis, patients who carried TT genotype and CT + TT genotype of GSTP1 IIe105Val showed a significant poorer tumor response to chemotherapy when compared with CC genotype (for TT genotype, adjusted OR = 0.44, 95 % CI = 0.22–0.89; for CT + TT genotype, adjusted OR = 0.59, 95 % CI = 0.39–0.92). By Cox multivariate analysis, TT genotype and CT + TT genotype were associated with increased risk of death from breast cancer, and the relationship was more obvious after being adjusted by potential confounding factors (for TT genotype, adjusted OR = 4.23, 95 % CI = 2.33–8.76; for CT + TT genotype, adjusted OR = 2.53, 95% CI = 1.60–4.03). Polymorphism of GSTP1 IIe105Val might affect the clinical outcome in breast cancer patients.

Keywords

Breast cancer Glutathione S-transferases Polymorphism Response to chemotherapy Overall survival 

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Carol D, Jiemin M, Leah B, Ahmedin J. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62.CrossRefGoogle Scholar
  3. 3.
    Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286(5439):487–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005;6(10):780–9.CrossRefPubMedGoogle Scholar
  5. 5.
    André F, Ciccolini J, Spano JP, Penault-Llorca F, Mounier N, Freyer G, et al. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics. 2013;14(8):931–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res. 2000;463(3):247–83.CrossRefPubMedGoogle Scholar
  7. 7.
    Ruzza P, Rosato A, Rossi CR, Floreani M, Quintieri L. Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem. 2009;9(7):763–77.CrossRefPubMedGoogle Scholar
  8. 8.
    Oliveira AL, Oliveira Rodrigues FF, Dos Santos RE, Rozenowicz RL, Barbosa de Melo M. GSTT1, GSTM1, and GSTP1 polymorphisms as a prognostic factor in women with breast cancer. Genet Mol Res. 2014;13(2):2521–30.CrossRefPubMedGoogle Scholar
  9. 9.
    Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, et al. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Mol Diagn Ther. 2013;17(6):371–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Bai YL, Zhou B, Jing XY, Zhang B, Huo XQ, Ma C, et al. Predictive role of GSTs on the prognosis of breast cancer patients with neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 2012;13(10):5019–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Mishra A, Chandra R, Mehrotra PK, Bajpai P, Agrawal D. Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. Surg Today. 2011;41(4):471–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMedGoogle Scholar
  13. 13.
    Wheeler HE, Gamazon ER, Stark AL, O’Donnell PH, Gorsic LK, Huang RS, et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013;13:35–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54(16):4313–20.PubMedGoogle Scholar
  15. 15.
    Oguri T, Fujiwara Y, Katoh O, Daga H, Ishikawa N, Fujitaka K, et al. Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. Cancer Lett. 2000;156:93–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Ge J, Tian AX, Wang QS, Kong PZ, Yu Y, Li XQ, et al. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China. PLoS One. 2013;8(6):e67589.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, et al. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Mol Diagn Ther. 2013;17(6):371–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Duggan C, Ballard-Barbash R, Baumgartner RN, Baumgartner KB, Bernstein L, McTiernan A. Associations between null mutations in GSTT1 and GSTM1, the GSTP1 Ile (105) Val polymorphism, and mortality in breast cancer survivors. Springerplus. 2013;2:450.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bai YL, Zhou B, Jing XY, Zhang B, Huo XQ, Ma C, et al. Predictive role of GSTs on the prognosis of breast cancer patients with neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 2012;13(10):5019–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Liu J, Luo J, Wang Y, Li L, Yang S. Predictive potential role of glutathione S-transferases polymorphisms on prognosis of breast cancer. Int J Clin Exp Pathol. 2014;7(12):8935–40.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Liang Zhou
    • 1
  • Anzhong Huang
    • 1
  • Dawei Zhang
    • 1
  • Junliang Yao
    • 1
  • Yong Zhang
    • 1
  • Xuejiao Li
    • 2
  1. 1.Department of General Surgery, Jinshan HospitalFudan UniversityShanghaiChina
  2. 2.Clinical medicineChengdu Medical CollegeChengduChina

Personalised recommendations